Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells by Ando, Seijitsu et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
Respiratory Research
Open Access Research
Proteinase-activated receptor 4 stimulation-induced 
epithelial-mesenchymal transition in alveolar epithelial cells
Seijitsu Ando1,2, Hitomi Otani1, Yasuhiro Yagi2, Kenzo Kawai3, 
Hiromasa Araki3, Shirou Fukuhara2 and Chiyoko Inagaki*1
Address: 1Department of Pharmacology, Kansai Medical University, 10-15, Fumizono-Cho, Moriguchi, Osaka 570-8506, Japan, 2The First 
Department of Internal Medicine, Kansai Medical University, 10-15, Fumizono-Cho, Moriguchi, Osaka 570-8506, Japan and 3Fuso 
Pharmaceutical Industries, Ltd., Joto-ku, Osaka 536-8523, Japan
Email: Seijitsu Ando - andos@takii.kmu.ac.jp; Hitomi Otani - otani@takii.kmu.ac.jp; Yasuhiro Yagi - yagiy@takii.kmu.ac.jp; Kenzo Kawai - k-
kawai@fuso-pharm.co.jp; Hiromasa Araki - h-araki@fuso-pharm.co.jp; Shirou Fukuhara - fukuhara@takii.kmu.ac.jp; 
Chiyoko Inagaki* - inagaki@takii.kmu.ac.jp
* Corresponding author    
Abstract
Background: Proteinase-activated receptors (PARs; PAR1–4) that can be activated by serine
proteinases such as thrombin and neutrophil catepsin G are known to contribute to the
pathogenesis of various pulmonary diseases including fibrosis. Among these PARs, especially PAR4,
a newly identified subtype, is highly expressed in the lung. Here, we examined whether PAR4
stimulation plays a role in the formation of fibrotic response in the lung, through alveolar epithelial-
mesenchymal transition (EMT) which contributes to the increase in myofibroblast population.
Methods: EMT was assessed by measuring the changes in each specific cell markers, E-cadherin
for epithelial cell, α-smooth muscle actin (α-SMA) for myofibroblast, using primary cultured mouse
alveolar epithelial cells and human lung carcinoma-derived alveolar epithelial cell line (A549 cells).
Results: Stimulation of PAR with thrombin (1 U/ml) or a synthetic PAR4 agonist peptide (AYPGKF-
NH2, 100 μM) for 72 h induced morphological changes from cobblestone-like structure to
elongated shape in primary cultured alveolar epithelial cells and A549 cells. In immunocytochemical
analyses of these cells, such PAR4 stimulation decreased E-cadherin-like immunoreactivity and
increased α-SMA-like immunoreactivity, as observed with a typical EMT-inducer, tumor growth
factor-β (TGF-β). Western blot analyses of PAR4-stimulated A549 cells also showed similar
changes in expression of these EMT-related marker proteins. Such PAR4-mediated changes were
attenuated by inhibitors of epidermal growth factor receptor ( E G F R )  k i n a s e  a n d  S r c .  P A R 4-
mediated morphological changes in primary cultured alveolar epithelial cells were reduced in the
presence of these inhibitors. PAR4 stimulation increased tyrosine phosphorylated EGFR or tyrosine
phosphorylated Src level in A549 cells, and the former response being inhibited by Src inhibitor.
Conclusion: PAR4 stimulation of alveolar epithelial cells induced epithelial-mesenchymal transition
(EMT) as monitored by cell shapes, and epithelial or myofibroblast marker at least partly through
EGFR transactivation via receptor-linked Src activation.
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Background
Proteinase-activated receptors (PARs) are newly identified
G-protein-coupled receptors that can be activated by ser-
ine proteinases such as thrombin, trypsin, mast cell tryp-
tase and neutrophil cathepsin G [1,2]. These proteinases
cleave the extracellular amino terminal domain of PARs to
create a new NH2 terminal sequence, which functions as a
tethered ligand to initiate each receptor-coupled cell sign-
aling. To date, four PARs have been cloned; PAR1, PAR3
and PAR4 are preferentially activated by thrombin, while
PAR2 are selectively activated by trypsin [2]. In the respira-
tory system, PAR1, PAR2 and PAR4 are expressed at differ-
ent levels depending on the tissues or the cell types
(epithelium, endothelium, tracheal smooth muscle and
blood vessel), and reportedly modulate cytoskeletal struc-
ture and further contribute to the progression of various
airway and lung disorders including inflammation and
fibrosis [2-4]. For example, in systemic sclerosis patients
with pulmonary fibrosis or idiopathic pulmonary fibrosis
(IPF) patients, concentrations of thrombin and/or cathep-
sin G in bronchoalveolar lavage fluid are much higher
than those in healthy controls [5,6]. Therefore, thrombin
receptors such as PAR1 and/or PAR4 in lung are thought to
contribute to the pathogenesis of lung fibrosis. Indeed,
Howell et al [3] demonstrated that bleomycin-induced
fibrotic responses such as collagen accumulation and
increases in profibrotic mediator levels were attenuated by
PAR1-knockout, suggesting the involvement of PAR1 sig-
nal in the pathogenic mechanisms. However, contribu-
tion of another thrombin receptor, PAR4, has not been
examined. In our recent study, PAR4 (mRNA/protein) has
been demonstrated to be highly expressed in primary cul-
tured mouse alveolar epithelial cells [7]. This enabled us
to test the involvement of PAR4 stimulation in pathoge-
netic mechanisms of fibrosis in vitro.
Pulmonary fibrosis is a final common endpoint patho-
mechanism in various lung diseases including acute respi-
ratory distress syndrome (ARDS) [8]. The process is
characterized by multiple phenomena such as epithelial
activation and damage, an excessive extracellular matrix
deposition and a substantial increase in the number of
fibroblasts/myofibroblasts [9], transforming growth fac-
tor-β (TGF-β), interleukin-4 and tumor necrosis factor-α
being known as inducers of such fibrotic responses [8,9].
Recently, phenotypic transition of epithelial cell to mes-
enchymal cell (epithelial-mesenchymal transition; EMT)
has received attention as an important mechanism of pro-
gressive increase in the number of myofibroblasts in vari-
ous fibrotic tissues including kidney and lung [10-12].
Typical alveolar epithelia form a cobblestone-like sheet
structure that tightly adhering to neighboring cells or var-
ious basal substrates, and play an active role in protecting
lung from injury and infection [13]. Under persistent lung
pathogenic insults, integrity and characteristics of alveolar
epithelium are disturbed and rearranged to induce mor-
phological or physiological alterations, for example, a loss
of cell-cell contact, apoptosis and proliferation. Further,
parts of epithelial cells are phenotypically changed to dif-
ferent types of cells like mesenchymal cell, i.e., EMT
[9,12]. During EMT, the epithelial cells lose their charac-
teristic morphology through a various intermediate stages
like a loss of epithelial adhesion molecules such as E-cad-
herin (a specific epithelial marker) and secretion of matrix
metalloproteinase (MMP). Finally, cells are converted to a
mesenchymal phenotype and acquire myofibloblast mor-
phology characterized by an elongated cell shape and de
novo expression of α-smooth muscle actin (α-SMA, a hall-
mark of myofibroblast). In several different studies, not
only growth factor such as TGF-β, epidermal growth factor
(EGF) and interleukin-1 but also some drugs
(cyclosporine A and angiotensin ll) have been shown to
induce EMT of tubular and alveolar epithelial cells,
thereby facilitating the progression of renal and lung
fibrosis [8,10,14-16].
In the present study, we examined whether stimulation of
PAR4 which is known to be involved in the long-scale cel-
lular responses [17] modulates epithelial morphology
through EMT using primary cultured mouse alveolar epi-
thelial cells and a human lung carcinoma-derived alveolar
epithelial cell line (A549 cells). Possible mechanisms of
the PAR4's effects were also analyzed with respect to the
involvement of EGF receptor (EGFR) signaling, since this
receptor is reportedly transactivated by various extracellu-
lar stimuli such as G protein-coupled receptors including
PARs [18-20].
Methods
Materials
An agonist peptide for PAR4 (AYPGKF-NH2), and an inac-
tive reverse sequence peptide (FKGPYA-NH2) were syn-
thesized by Fuso Pharmaceutical Industries, LTD.,
Research and Development Center (Osaka, Japan).
Thrombin and monoclonal anti-α-smooth muscle actin
(α-SMA) antibody (Fluorescein isothiocyanate (FITC)
conjugated purified mouse immunoglobulin) were pur-
chased from Sigma chemicals (St. Louis, MO, USA). Jok-
lik's modification Eagle's medium (JMEM), Dulbecco's
modification Eagle's media (DMEM) and fetal calf serum
(FCS) were from Gibco BRL Life Technologies (Grand
Island, NY, USA); human TGF-β1 was from Peprotech EC
(Margravine Rode, London, UK); antibodies against E-
cadherin, GAPDH and phospho-EGFR (specific for
Tyr1173) were from Santa Cruz Biotechnology, Inc.,
(Santa Cruz, CA, USA); anti-Src and anti-phospho-Src
(specific for Tyr416) antibodies were from Cell Signaling
Technology, INC (Danvers, MA, USA); 4-Amino-5-(4-
chlorophenyl)-7-(t-butyl) pyrazolo [3,4-d pyrimidine
(PP2) and 4-(3-Chloroanilino-6,7-dimethoxyquinazo-Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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line (AG1478) were from BIOMOL International, L.P.,
(Matford court, UK); rhodamine red-conjugated goat
anti-rabbit IgG was from Jakson Immunoresearch Labora-
tories, (West Grove, PA, USA); peroxidase-conjugated
goat anti-rabbit or anti-mouse immnogloblin was from
Cappel, ICN Pharmaceutical, Inc., (Aurora, OH, USA) or
Zymed Laboratories Inc., (South San Francisco, CA, USA),
respectively; ECL (enhanced chemiluminescence) kit was
from NEN Life Science Product (Boston, MA, USA); and
SCH-79797 dihydrochloride [(N3-Cyclopropyl-7-[[4-(1-
methylethyl)phenyl]methyl]-7H-pyrrolo [3,2-f]quinazo-
line-1,3-diamine dihydrochloride was from Tocris Cook-
son Ltd. (Bristol, BS11 9XJ, UK). All other chemicals were
purchased from Wako Pure Chemical (Osaka, Japan) and
of the highest purity available.
Preparation of primary cultured alveolar epithelial cells
All animals were handled in accordance with the "Rules of
Animal Experimentation Committee, Kansai Medical
University".
Healthy C57BL/6J mice (20–25 g) were anesthetized with
intraperitoneal injection of pentobarbital (1.5 mg/10 g
body weight). Primary cell culture was accomplished
using protocol described previously with a slight modifi-
cation [21]. Briefly, the pulmonary vessel was perfused via
the right cardiac ventricle with saline. The trachea was can-
nulated with 3 Fr tubing, and the lung was filled with 1–2
ml of JMEM containing 0.1 % dispase (Godo-shusei,
Tokyo, Japan) and 0.45 ml of low-melting-point agarose.
The lung was then placed in ice-cold JMEM for 2 min to
harden the agarose and incubated in 2 ml of the dispase
solution for 20 min at room temperature. The lung was
teased from the airways and minced in DMEM supple-
mented with penicillin (100 units/ml), streptomycin (100
μg/ml) and amphotericin B (0.75 μg/ml). The minced
lung tissues were filtered successively through 133-, 42-,
and 22-μm nylon mesh, and centrifuged at 130 g for 8
min. The resulting pellets were dispersed with DMEM sup-
plemented with 10 % FCS and then plated on a petri dish
for 4 h to remove mesenchymal cells and the floating cells
(non adherent cells) were plated on fibronectin (Chemi-
conez-International, Temecula, CA, USA)-coated circular
glass coverslips placed in the plastic dishes at density of
20000/dish. The viability of the isolated cells was checked
by trypan-blue exclusion and was found to be greater than
98 %. Cells were maintained in DMEM supplemented
with 10 % fetal calf serum at 37°C in 5 % CO2 and 95 %
air. On the day 7 of culture, cells were immunocytochem-
ically characterized using antibodies against pan-cytoker-
atin (which recognize cytokelatin 1–8, 10, 14–16, 19)
(Nichirei Bioscience, Tokyo Japan) and vimentin (Dako,
Carpinteria, CA, USA) as respective markers for epithelial
cell and fibroblast. The majority of the cultured cells were
epithelial cells with a uniform cobblestone pattern [21].
The contamination of fibroblasts was below 10 %. Macro-
phages or lymphocytes were not detected on the immno-
cytochemical analyses using antibodies against respective
markers (Mac1 and CD45). Such cultures were subjected
to experiments.
Cell culture of A549 cells
A549 cells (human lung carcinoma-derived alveolar epi-
thelial cell line) were cultured in DMEM supplemented
with penicillin (100 units/ml), streptomycin (100 μg/ml),
amphotericin B (0.75 μg/ml) and 10 % FCS at 37°C in 5
% CO2 and 95 % air. A549 cells were grown to 90 % con-
fluence in 10 cm plastic culture dishes and harvested by
exposure to 0.05 % trypsin and 0.02 % EDTA followed by
centrifugation at 90 g for 1 min. The resulting pellets were
resuspended in DMEM solution with the supplements
and plated on the culture dishes for Western blotting anal-
yses. After incubation at 37°C for 3 days to achieve 70–
90% confluent monolayer, the cells were incubated in
DMEM with or without 1 % FCS depending on experi-
mental protocol.
Immunocytochemistry in primary cultured alveolar 
epithelial cells and A549 cells
Primary cultured alveolar epithelial cells grown on cover-
slips glass incubated with DMEM containing 1 % FCS
were stimulated with or without thrombin, AYPGKF-NH2
and TGF-β for 72 h at 37°C. The cells were fixed for 5 min
with 1 % paraformaldehyde in a phosphate-buffered solu-
tion (PBS) containing 136.9 mM NaCl, 2.1 mM KCl, 3.2
mM Na2HPO4 and 1.5 mM KH2PO4, pH 7.4, and were
washed twice with PBS. Fixed cells were permeated with 1
% Triton X-100 for 5 min, and were washed twice with
PBS solution. The cells were incubated with monoclonal
antibody against E-cadherin in PBS containing 2 mg/ml
bovine serum albumin (BSA) for 2 h at room temperature.
The cells were then incubated with FITC-conjugated mon-
oclonal antibody against α-SMA and rhodamin red-con-
jugated goat anti-rabbit IgG and for 1 h at room
temperature. On the other hand, after incubation with E-
cadherin, A549 cells were incubated with monoclonal
antibody against α-SMA (Nichirei Bioscience, Tokyo
Japan) for 1 h at room temperature. Then, the cells were
incubated with FITC-conjugated goat anti-mouse IgG and
rhodamin red-conjugated goat anti-rabbit IgG and for 1 h
at room temperature. Coverslips with the cells were
mounted on a slide and visualized using confocal laser
microscopy system (LSM 510-META; Carl Zeiss, Iena, Ger-
many) with a water immersion objective lens for high res-
olution; 8 frames per slide were captured. Aperture, gain
and black level for image acquisition were maintained at
a constant level.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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Prepareation of cell lysates
A549 cells were stimulated with test drugs in DMEM in
the presence (for E-cadherin and α-SMA detection) or
absence (for pEGFR and pSrc detection) of 1 % FCS for the
indicated periods followed by harvest. The cells were lysed
at 4°C in the two kinds of cold lysis buffer. Triton buffer
containing 30 mM HEPES (pH 7.1), 100 mM NaCl, 1 mM
EGTA, 20 mM NaF, 1 % Triton X-100, 1 mM phenylmeth-
ylsulphonylfluoride (PMSF) and 20 μl/ml protease inhib-
itor cocktail (Roche Diagnostics GmbH, Mannheim,
Germany) were used for detection of E-cadherin and α-
SMA. RIPA (radio immunoprecipitation assay) buffer (pH
7.4) containing 100 mM HEPES, 300 mM NaCl, 2 mM
EDTA, 2 % Nonidet P40, 1 % sodium deoxycholate, 0.2 %
sodium lauryl sulfate (SDS), 3 mM MgSO4, 200 U/ml
aprotinin, 20 μg/ml leupeptin, 1 mM PMSF, 100 mM NaF,
10 mM orthovanadate and 20 μl/ml protease inhibitor
cocktail were used for detection of EGFR or Src phospho-
rylation. Both lysates obtained with each method were
centrifuged 9000 g for 5 min. The supernatants were
mixed with a SDS-Laemmli sample buffer and boiled for
2 min. Protein concentrations of the samples were meas-
ured using the Bio-Rad protein assay (Bio-Rad Laborato-
ries, Hercules, CA, USA).
Western blot analysis
Equal amounts of samples (20 μg/lane) were separated on
7.5 % SDS-polyacrylamide gel electrophoresis and trans-
ferred to an immobilon P membrane (Millipore Corpora-
tion, Bedford, MA, USA) using an electroblotting
apparatus. The membrane was blocked with 5 % non-fat
milk or 1 % BSA (for phosphorylated antibody) in Tris-
Typical phase contrast images of primary cultured mouse alveolar epithelial cells Figure 1
Typical phase contrast images of primary cultured mouse alveolar epithelial cells. Epithelial cells were treated for 
72 h without agonist (control) or with thrombin (1 U/ml), PAR4 agonist peptide (AYPGKF-NH2, 100 μM) or TGF-β (5 ng/ml).Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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buffered saline (TBS; 50 mM Tris and 150 mM NaCl, pH
7.5) for 1 h at room temperature. The membrane was
incubated with each primary antibody overnight at 4°C.
The membrane was then washed and incubated for with
peroxidase-conjugated goat anti-rabbit or anti-mouse
immunogloblin for 1 h at room temperature. The mem-
brane was visualized by the enhanced chemiluminescence
method. To confirm equal loading, the same membranes
were stripped by incubating in a solution containing 100
mM 2-mercaptoethanol, 2 % SDS and 62.5 mM Tris-HCl
(pH 6.8) for 1 h at 50°C, then blotted with the anti-
GAPDH, anti-Src or anti-EGFR antibody.
The signal intensities were measured with a densitometer
(DMU-33C; Advantec Digital Densitol, Tokyo, Japan).
Statistical analysis
Statistical analyses were performed by ANOVA and Bon-
ferroni's test. When only two groups were compared, Stu-
dent's t-test was used for statistical analysis. The
differences between mean values with P values less than
0.05 were considered significant.
Results
Morphological changes induced by PAR4 agonists
Figure 1 shows the typical morphological images of pri-
mary cultured alveolar epithelial cells assessed by phase
contrast microscopy. Control cells formed monolayer in
which individual cells displayed typical cobblestone-like
shape and were tightly attached to each other. In contrast,
after exposure to thrombin (1 U/ml) or a PAR4 agonist
peptide (AYPGKF-NH2, 100 μM) for 72 h, many cells
showed an elongated shape and lost cell-cell contact.
When the cells were treated with TGF-β (5 ng/ml), a
potent EMT inducer [8,10,22], such a morphological
change was obvious, showing an extremely elongated
shape like fibroblasts. PAR4 stimulation of alveolar epithe-
lial cells thus appeared to induce phenotypic changes to
mesenchymal-like cells.
Phenotypic changes in primary cultured alveolar epithelial cells stimulated with PAR4 agonists or TGF-β Figure 2
Phenotypic changes in primary cultured alveolar epithelial cells stimulated with PAR4 agonists or TGF-β. 
Immunofluorescence images for a specific marker for epithelial cell (E-cadherin; rhodamine red, upper panel) or myofibroblast 
(α-SMA; FITC green, lower panel) captured with confocal lasar microscopy. Cells were treated with or without (control) vari-
ous agonists (thrombin, AYPGKF-NH2 or TGF-β) for 72 h, and stained for E-cadherin or α-SMA using specific antibodies as 
described in Method section.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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Changes in cell structure induced by PAR4 stimulation
To address whether PAR4 stimulation induces EMT in the
primary cultured alveolar epithelial cells, changes in
expression pattern of epithelial or myofibroblast marker
was immunocytochemically analyzed. Figure 2 shows a
representative immunofluorescence image of expression
of E-cadherin or α-SMA, a typical marker of epithelial cell
or myofibroblast, respectively. After 72 h exposure of the
cells to either of PAR4 agonists, E-cadherin expression was
significantly decreased concomitantly with reduced cell-
cell contact and loss of epithelial morphology. In contrast,
strong expression of α-SMA-positive microfilaments
became clearly observed in the cytoplasmic peripheral
area by the same treatments as compared with non-evi-
dent expression in control without stimulation. TGF-β(5
ng/ml, 72 h) used as a typical EMT inducer showed a
marked decrease or increase in expression of E-cadherin or
α-SMA, respectively. Such EMT responses were also
observed in alveolar epithelial cell line (A549 cells) stim-
ulated with PAR4 agonists and TGF-β(5 ng/ml) for 72 h
(Fig. 3). In the next experiment, such immunocytochemi-
cal changes in E-cadherin and α-SMA expression was sub-
stantiated by Western blot analyses using A549 cells.
As shown in Figure 4A, treatment of A549 cells with
thrombin (1 and 5 U/ml, 96 h) decreased the amount of
immunoreactive E-cadherin (molecular mass, 135 kD),
and increased α-SMA (molecular mass, 42 kD), compared
with time-matched control (no treatment). A similar
response to AYPGKF-NH2 (100 μM, 96 h), but not to a
FKGPYA-NH2  (PAR4-inactive reverse sequence peptide,
100 μM), was also observed, suggesting the response to
agonist peptide due to specific PAR4 stimulation (Figure
4B). Figure 4C and 4D show the pooled data obtained
from 4–12 preparations. PAR4-mediated changes in
expression level of each marker protein (decreases in E-
cadherin or increases in α-SMA) were quantitated by the
densitometric analyses. Reverse sequence peptide (FKG-
PYA-NH2, inactive form) at the same concentration (100
μM) did not show significant changes in the expressions
of both marker proteins.
Phenotypic changes in A549 cells stimulated with PAR4 agonists or TGF-β Figure 3
Phenotypic changes in A549 cells stimulated with PAR4 agonists or TGF-β. Immunofluorescence images for a spe-
cific marker for epithelial cell (E-cadherin; rhodamine red, upper panel) or myofibroblast (α-SMA; FITC green, lower panel) 
captured with confocal lasar microscopy. Cells were treated with or without (control) various agonists (thrombin, AYPGKF-
NH2 or TGF-β) for 72 h, and stained for E-cadherin or α-SMA using specific antibodies as described in Method section.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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Thrombin-induced changes in each marker protein were
not significantly affected by the PAR1-selective antagonist
(SCH-79797, 300 nM) (E-cadherin; 78.3 ± 3.2 % or 75.6
± 4.0 % of untreated group, α-SMA; 211.4 ± 23.6 % or
240.4 ± 45.6 % of untreated group, in thrombin-stimu-
lated cells without or with inhibitor, respectively, mean ±
S.E.M., n = 5), suggesting that the possibility of the partic-
ipation of PAR1 in the thrombin action is unlikely. A
potent EMT inducer, TGF-β (5 ng/ml) showed changes
similar to those with PAR4 agonists.
In accordance with our observation, such a TGF-β-
induced EMT in A549 cells was also detected by previous
report [22,23]. Thus, PAR4 stimulation induced EMT in
alveolar epithelial cells.
Effects of inhibitors of EGF receptor kinase and Src kinase 
on PAR4-mediated EMT
PARs reportedly transactivates, i.e., phosphorylates, EGFR
in a variety of cell systems such as gastric cancer cells and
cardiac myocytes [18,24], and phosphorylated EGFR trig-
gers EMT in human ovarian surface epithelium [25].
Therefore, we examined whether EGFR is involved in the
PAR4-mediated EMT, using an EGFR kinase inhibitor,
AG1478 (Ki at 3 nM). As shown in Figure 5A (summa-
rized in C and D), AG1478 inhibited both of the PAR4
stimulation-induced changes in the EMT parameters (E-
cadherin and α-SMA), suggesting that EGFR signaling is
involved in the PAR4-mediated EMT. Since EGFR transac-
tivation is reportedly promoted by Src (18,24), the effects
of PP2 (300 nM, a Src family tyrosine kinase inhibitor)
Western blot analyses of E-cadherin and α-SMA in A549 epithelial cells stimulated with PAR4 agonists and TGF-β Figure 4
Western blot analyses of E-cadherin and α-SMA in A549 epithelial cells stimulated with PAR4 agonists and 
TGF-β. (A, B) Representative Western blots of E-cadherin and α-SMA in A549 cells treated for 96 h with thrombin (A; 1 or 5 
U/ml) or synthetic peptides (B; AYPGKF-NH2 or FKGPYA-NH2; 100 μM). (C, D) Summarized densitometric data. Effects of 
PAR4 agonists (thrombin; 1 U/ml and AYPGKF-NH2; 100 μM), FKGPYA-NH2 (100 μM) or TGF-β (5 ng/ml) on the expressions 
of E-cadherin (C) and α-SMA (D). Results are based on densitometric analyses of the ratio of each marker protein to GAPDH 
(as internal standard). Each bar represents the mean ± S.E.M. from 4–12 preparations. **P < 0.01 compared with the control.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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Effects of inhibitors of EGFR tyrosine kinase and Src tyrosine kinase on PAR4 agonist-induced changes in EMT-related marker  protein expression in A549 cells Figure 5
Effects of inhibitors of EGFR tyrosine kinase and Src tyrosine kinase on PAR4 agonist-induced changes in EMT-
related marker protein expression in A549 cells. A549 cells were pretreatd with or without 30 nM AG1478 or 300 nM 
PP2 for 30 min, and then stimulated with AYPGKF-NH2 (100 μM) for 96 h followed by immunoblotting with specific antibodies 
for E-cadherin, α-SMA. (A, B) Representative Western blots for the effect of AG1478 (A) or PP2 (B) on the expression of E-
cadherin and α-SMA. (C, D) Summarized densitometric data. Each bar represents the mean ± S.E.M. for 4–12 preparations. *P 
< 0.05 compared with AYPGKF-NH2 alone.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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PAR4 agonist-induced EGFR phosphorylation in A549 cells Figure 6
PAR4 agonist-induced EGFR phosphorylation in A549 cells. A549 cells were pretreated with or without 300 nM PP2 
for 30 min, and then stimulated with AYPGKF-NH2 (100 μM) for 30–60 min followed by immunoblotting with specific antibod-
ies for the Y1173 phosphorylated EGFR and total EGFR protein. Control; without drug treatment. (A) Representative time 
course of EGFR phosphorylation induced by thrombin (1 U/ml) or AYPGKF-NH2 (100 μM). As a positive control, cells were 
treated with EGF (10 ng/ml) for 30 min. (B) Representative Western blot after treatment with or without (control) various 
agents (AYPGKF-NH2, AYPGKF-NH2+PP2, 100 μM FKGPYA-NH2 or EGF) for 30 min. (C) Summarized densitometric data. 
Protein concentrations used for separation was 20 μg/lane (thrombin or AYPGKF-NH2 or FKGPYA-NH2 treated sample) or 
10 μg/lane (EGF treated sample). Each bar represents the mean ± S.E.M. for 4–6 preparations. *P < 0.05 compared with 
AYPGKF-NH2 alone.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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Western blot analyses of Src phosphorylation in A549 cells Figure 7
Western blot analyses of Src phosphorylation in A549 cells. A549 cells were treated without (control) or with 
AYPGKF-NH2 (100 μM) for 10, 30 or 60 min or with thrombin (1 U/ml, 10 min) or with FKGPYA-NH2 (100 μM, 10 min), and 
then subjected to immunoblotting with specific antibodies for the Y418 phosphorylated Src and total Src protein. (A) Repre-
sentative Western blot. Stimulation time was 10 min. (B) Summarized densitometric data. Each bar represents the mean ± 
S.E.M. for 4–6 preparations. **P < 0.01, *P < 0.05 compared with the control.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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were also examined. As shown in Figure 5B (summarized
in C and D), PP2 inhibited the PAR4-mediated changes in
E-cadherin and α-SMA expression, suggesting the involve-
ment of Src signaling in the PAR4-mediated EMT.
PAR4 stimulation-induced phosphorylation of EGF 
receptor and Src
PAR4 stimulation induced phosphorylation of EGFR was
examined. In A549 cells stimulated with thrombin (1 U/
ml) or AYPGKF-NH2  (100  μM) for 30 or 60 min,
tyrosine1173 phosphorylated EGFR (pEGFR) level was
obviously elevated (Figure 6A and 6C). Such induction of
pEGFR by PAR4 stimulation occurred as early as 30 min
after the agonist application. EGF (10 ng/ml) as a positive
control induced a marked increase in EGFR phosphoryla-
tion. Further, this PAR4 stimulation-induced increase in
pEGFR level was significantly inhibited by PP2 (Figure 6B
and 6C), suggesting that Src may be an upstream signaling
pathway for the PAR4 stimulation-induced EGFR transac-
tivation. EGFR phosphorylation was not observed by the
stimulation with FKGPYA-NH2 (100 μM) for 30 min.
To test whether PAR4 stimulation activates Src, the level of
Tyr416 phosphorylated Src (pSrc, activated form of Src)
was measured. As shown in Figure 7, stimulation of A549
cells with PAR4-agonist peptide (AYPGKF-NH2, but not
FKGPYA-NH2, caused a rapid phosphorylation of Src.
Thrombin (1 U/ml, 10 min) also induced an increase in
pSrc level. PAR4 stimulation thus activated Src followed by
EGFR transactivation to produce EMT in lung alveolar epi-
thelial cells.
The effects of EGFR kinase and Src kinase inhibitors on 
PAR4 stimulation-induced phenotypic changes in primary 
cultured alveolar epithelial cells
Finally, we immunocytochemically analysed the expres-
sion of E-cadherin and α-SMA in the primary cultured
alveolar epithelial cells exposed to AYPGKF-NH2 (100
μM, 72 h) in the presence of EGFR kinase inhibitor
(AG1478, 30 nM) or Src family tyrosine kinase inhibitor
(PP2, 300 nM). As shown by representative fluorescence
imaging data in Figure 8, pretreatment with each inhibitor
for 30 min obviously reduced the PAR4 agonist peptide-
Effects of AG1478 and PP2 on PAR4 agonist induced phenotypic changes in primary cultured alveolar epithelial cells Figure 8
Effects of AG1478 and PP2 on PAR4 agonist induced phenotypic changes in primary cultured alveolar epithelial 
cells. Immunofluorescence images for a specific marker for epithelial cell (E-cadherin; rhodamine red, upper panel) or myofi-
broblast (α-SMA; FITC green, lower panel) captured with confocal lasar microscopy. Cells were treated with or without (con-
trol) AYPGKF-NH2 (100 μM) for 72 h in the presence or absence of each inhibitor (30 nM AG1478 or 300 nM PP2), and 
stained using each specific antibody as described in Method section.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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induced EMT parameter responses (loss of cell-cell con-
tact, decrease in expression of E-cadherin and increase in
expression of α-SMA), reinforcing the Western blot data.
Each inhibitor alone unaffected cell morphology (data
not shown).
Discussion
In the present study, we showed that PAR4 stimulation of
alveolar epithelial cells (primary cultured mouse epithe-
lial cells and human A549 cell line) for 72–96 h resulted
in the loss of a marker for epithelial cell (E-cadherin) and
induction of a marker of myofibroblast (α-SMA). This is
the first report demonstrating that PAR4  stimulation
induces EMT in the primary cultured alveolar epithelial
cells. Since these phenotypic changes were inhibited by
inhibitors of EGFR kinase (AG1478) or Src family tyrosine
kinase (PP2), the Src/EGFR-regulated mechanism is
assumed to underlie the induction of EMT.
Molecular mechanisms of EMT induction are not clarified
yet. A typical EMT inducer, TGF-β reportedly activate
Smad 2 or Smad 3 signaling [10,12] or Rho/ROCK signal-
ing [25] to induce EMT. Activated Smads translocate into
the nucleus and facilitate transcription of target genes, for
example α-SMA. Besides these signaling, the present find-
ings showed new EMT-producing signaling pathway
including activation of Src and EGFR.
Salient findings in this study were as follows; 1) PAR4
stimulation of alveolar epithelial cells induced morpho-
A schematic illustration summarizing the mechanisms for PAR4-mediated EMT in alveolar epithelial cell Figure 9
A schematic illustration summarizing the mechanisms for PAR4-mediated EMT in alveolar epithelial cell. Bold 
line: a new pathway proposed in this study. Dotted line: other mechanisms.Respiratory Research 2007, 8:31 http://respiratory-research.com/content/8/1/31
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logical change to fibroblast-like cell shape, 2) changes in
EMT parameters in response to PAR4 agonist (AYPGKF-
NH2) were suppressed by inhibitors of EGFR (AG1478)
and Src family (PP2) tyrosine kinases, 3) PAR4 stimulation
resulted in elevation of pSrc and pEGFR levels, the latter
being reduced in the presence of PP2. Based on these find-
ings, PAR4-mediated EMT is considered to be produced
through Src-mediated EGFR activation. Inhibitory effects
of AG1478 or PP2 on PAR4 stimulation-induced changes
in EMT parameters (Fig. 8) support our hypothesis. In line
with this idea, EGF reportedly enhances TGF-β-induced
EMT in human proximal tubular cells [27] and to induce
EMT in human ovarian surface epithelium [25]. Further,
treatment of A549 cells with EGF (10 ng/ml) for 96 h
induced a phenotypic change as demonstrated by expres-
sion of marker proteins (E-cadherin; **84.5 ± 2.2 %, α-
SMA; **305.5 ± 7.4% compared to respective untreated
group, mean ± S.E.M. n = 3, **P < 0.05, the author's
unpublished data). These informations reinforce the
involvement of EGFR stimulation in EMT development.
As downstream signaling to induce EMT after EGFR acti-
vation, enhanced activities of PI3 kinase, Akt, ERK and/or
p38 MAPK that regulate transcription of various target
proteins may be plausible candidates [25,28].
Conclusion
PAR4 stimulation of alveolar epithelial cells changed epi-
thelial shape, and induced a decrease or an increase in
expression of epithelial or myofibroblast marker, respec-
tively, which is suggestive of EMT. Receptor-linked Src
activation followed by EGFR transactivation was thought
to be involved in this PAR4-mediated phenotypic changes
in alveolar epithelial cells as summarized in Figure 9.
Selective inhibition of PAR4 and/or this receptor-related
signaling may yield a novel strategy to inhibit proteinase-
mediated development of pulmonary fibrosis.
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